Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 May;35(5):938–943. doi: 10.1128/aac.35.5.938

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.

C V Fletcher 1, J A Englund 1, C K Edelman 1, C R Gross 1, D L Dunn 1, H H Balfour Jr 1
PMCID: PMC245132  PMID: 1649575

Abstract

The incidence of cytomegalovirus disease, the most important infectious complication of renal transplantation, was reduced in renal allograft recipients by a regimen of prophylactic high-dose oral acyclovir. To analyze the pharmacologic aspects of our prophylactic approach, we evaluated safety, pharmacodynamics, and in vitro susceptibility data. One hundred four recipients of cadaveric renal allografts received either oral acyclovir (n = 53) in doses of up to 3,200 mg/day or a placebo (n = 51) for 12 weeks posttransplant. Leukocyte count and serum creatinine were selected as markers of laboratory safety and were evaluated pretransplant, at study midpoint (creatinine only), and at study completion. Concentrations of acyclovir in plasma were determined to verify the ability of the dosing strategy to achieve predicted values. Viral resistance was assessed by calculation of in vitro 50% inhibitory concentrations (IC50s) of acyclovir for the cytomegalovirus strains collected from the subjects. Our results showed no difference in leukocyte count or serum creatinine between the acyclovir and placebo recipients. Plasma acyclovir concentrations were maintained within the expected limits and did not differ between patients who developed cytomegalovirus disease and those who did not. The mean acyclovir IC50s for cytomegalovirus isolates were 42.6 mumol/liter in the acyclovir recipients and 48 mumol/liter in the placebo recipients. We conclude that the clinical benefit of high-dose oral acyclovir therapy occurred despite plasma drug concentrations below the mean IC50 for the patient viral isolates. Furthermore, the use of the regimen did not produce leukopenia, adversely affect renal function, or alter the susceptibility of cytomegalovirus strains to acyclovir. This approach and dose adjustment scheme may be appropriate for other immunocompromised patients at risk for cytomegalovirus infection and disease.

Full text

PDF
938

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Bean B., Mitchell C. D., Sachs G. W., Boen J. R., Edelman C. K. Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution. Am J Med. 1982 Jul 20;73(1A):241–248. doi: 10.1016/0002-9343(82)90099-7. [DOI] [PubMed] [Google Scholar]
  2. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  3. Biron K. K., Stanat S. C., Sorrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477. doi: 10.1073/pnas.82.8.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
  5. Dorsky D. I., Crumpacker C. S. Drugs five years later: acyclovir. Ann Intern Med. 1987 Dec;107(6):859–874. doi: 10.7326/0003-4819-107-6-859. [DOI] [PubMed] [Google Scholar]
  6. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  7. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  8. Fletcher C. V., Chinnock B. J., Chace B., Balfour H. H., Jr Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. Clin Pharmacol Ther. 1988 Aug;44(2):158–163. doi: 10.1038/clpt.1988.131. [DOI] [PubMed] [Google Scholar]
  9. Fryd D. S., Migliori R., Simmons R. L., Chavers B., Dunn D., Payne W., Canafax D. M., Sutherland D. E., So S. S., Mauer S. M. Renal transplantation at the University of Minnesota during the 1980s. Clin Transpl. 1987:167–181. [PubMed] [Google Scholar]
  10. HILL R. B., Jr, ROWLANDS D. T., Jr, RIFKIND D. INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION. N Engl J Med. 1964 Nov 12;271:1021–1027. doi: 10.1056/NEJM196411122712001. [DOI] [PubMed] [Google Scholar]
  11. Laskin O. L. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet. 1983 May-Jun;8(3):187–201. doi: 10.2165/00003088-198308030-00001. [DOI] [PubMed] [Google Scholar]
  12. Marker S. C., Howard R. J., Simmons R. L., Kalis J. M., Connelly D. P., Najarian J. S., Balfour H. H., Jr Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery. 1981 Jun;89(6):660–671. [PubMed] [Google Scholar]
  13. McGuffin R. W., Shiota F. M., Meyers J. D. Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro. Antimicrob Agents Chemother. 1980 Sep;18(3):471–473. doi: 10.1128/aac.18.3.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peterson P. K., Balfour H. H., Jr, Fryd D. S., Ferguson R. M., Simmons R. L. Fever in renal transplant recipients: causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med. 1981 Sep;71(3):345–351. doi: 10.1016/0002-9343(81)90149-2. [DOI] [PubMed] [Google Scholar]
  15. Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
  16. Sawyer M. H., Webb D. E., Balow J. E., Straus S. E. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988 Jun;84(6):1067–1071. doi: 10.1016/0002-9343(88)90313-0. [DOI] [PubMed] [Google Scholar]
  17. Sheiner L. B., Beal S. L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 Aug;9(4):503–512. doi: 10.1007/BF01060893. [DOI] [PubMed] [Google Scholar]
  18. Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986 Jan 23;314(4):208–212. doi: 10.1056/NEJM198601233140404. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES